Melinta Therapeutics ... has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.

Melinta is the latest in a long list of antibiotics firms that have hit trouble as big pharma is still unwilling to invest in the field, as it does not produce sufficient returns on investment.

Melinta and Alliance Partner Posters and Oral ... Our portfolio currently includes seven commercial-stage products: BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), MINOCIN ® (minocycline ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

PARSIPPANY, N.J., October 16, 2024--(BUSINESS WIRE)--Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses ...

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, ten scientific presentations with data ...

The panel voted 14 to 1 that the benefits of Cidara and Melinta Therapeutics' once-weekly echinocandin drug outweighed its risks as a first-line treatment for candidemia and invasive candidiasis ...